Drago J R
Division of Urology, Ohio State University, Columbus.
CA Cancer J Clin. 1989 Nov-Dec;39(6):326-36. doi: 10.3322/canjclin.39.6.326.
New as well as standard techniques for the detection and diagnosis of early prostate cancer have been described. These include the use of digital rectal examination, prostate-specific antigen, transrectal ultrasound, prostatic acid phosphatase, the Biopty gun, and cell ploidy, as well as the diagnosis of premalignant lesions of the prostate, such as prostatic dysplasia or, more appropriately, prostatic intraepithelial neoplasia. All of these innovations may enhance our ability to diagnose and follow patients with early prostate cancer. Full documentation and evaluation of long-term (15 to 20 years) follow-up, however, are needed to determine whether these new techniques will make a difference in the ultimate morbidity and mortality of prostate cancer in the United States. In the meantime, however, the use of these new diagnostic tools should not be avoided. We must advance with technology, and as the technologies grow and develop we should increase our understanding about the utility of each of these new tests and combine them with the older standard tests that have served us well for many years.
已描述了检测和诊断早期前列腺癌的新技术以及标准技术。这些技术包括直肠指检、前列腺特异性抗原、经直肠超声、前列腺酸性磷酸酶、活检枪和细胞倍体分析，以及前列腺癌前病变的诊断，如前列腺发育异常或更确切地说是前列腺上皮内瘤变。所有这些创新可能会提高我们诊断和随访早期前列腺癌患者的能力。然而，需要对长期（15至20年）随访进行全面记录和评估，以确定这些新技术是否会对美国前列腺癌的最终发病率和死亡率产生影响。不过，与此同时，不应避免使用这些新的诊断工具。我们必须与时俱进，随着技术的不断发展，我们应该加深对每种新检测方法效用的理解，并将它们与多年来一直为我们提供良好服务的旧标准检测方法相结合。
